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Abstract
Introduction Matrix metalloproteinases (MMPs) have re-
peatedly been shown to play a very active role in extracel-
lular matrix degradation associated with tumor invasion and
metastasis. Tissue inhibitors of MMPs (TIMPs) are well-
known for their ability to inhibit MMP activity thereby
inhibiting malignant progression. Inositol hexaphosphate
(IP6 phytic acid) has been recognized to have both preventive
and therapeutic effects against various cancers including that
of colon. In in vitro studies, IP6 has been demonstrated to
inhibit cancer cell adhesion and migration. In the present
study, the effect of IP6 on the expression of MMP and TIMP
genes was evaluated in unstimulated and IL-1β-stimulated
colon cancer cell line Caco-2.
Materials and methods Real-time QRT-PCR was used to
validate the transcription level of selected MMP and TIMP
genes in Caco-2 cells after treatment with 1 ng/ml of IL-1β,
2.5 mM of IP6, and both for 6, 12, and 24 h.
Results Stimulation of cells with IL-1β only resulted in an
overexpression of MMP and their TIMP mRNAs. A signif-
icant decrease in MMP-13, MMP-3, MMP-2, and TIMP-1
basal expression was achieved by IP6. IP6 was also an
efficient downregulator of MMP-1, MMP-9, and TIMP-2
genes transcription stimulated by IL-1β in 6 h lasting culture.
After 12 h, IL-1β-induced MMP-2 mRNA expression was
significantly reduced by IP6.
Conclusion Proinflammatory cytokine IL-1β upregulates
MMP and TIMP mRNAs expression in colon cancer epi-
thelial cells Caco-2. IP6 (2.5 mM) influences constitutive
expression of both MMP and TIMP genes and downregu-
lates IL-1β stimulated transcription of some of these genes.
IP6 exerts its anti-metastatic activity through modulation of
MMP and TIMP genes expression to prevent cancer cell
migration and invasion.
Introduction
Chronic inflammation is associated with a high cancer risk.
Inflammatory mediators are also present in the microenviron-
ment of tumors epidemiologically unrelated to inflammation.
Smouldering inflammation in local environment of tumors
induces many tumor-promoting effects. Cancer-related inflam-
mation contributes to proliferation and survival of malignant
cells, angiogenesis and metastasis, and represents a target for
therapeutic strategies [1]. Pro-inflammatory cytokines, such as
interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor-α
(TNF-α), actively participate in the promotion and progression
phases of carcinogenesis [2]. IL-1 is produced by components
of tumor microenvironment, such as tumor and stromal cells,
and infiltrated inflammatory/immune cells [3]. IL-1 is known
to be upregulated in many tumor types and it has been impli-
cated as an essential factor in tumor progression by influencing
the expression of metastatic and angiogenic genes. In various
experimental models and in cancer patients, the increased local
levels of IL-1 usually correlate with tumor invasiveness [4].
Tumor growth, invasion, and metastasis are multistep
processes that include cell proliferation, proteolytic diges-
tion of the extracellular matrix (ECM), cell migration
through basement membranes to reach the circulatory sys-
tem, and establishment of new proliferating colonies at the
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metastatic sites [5]. Cancer cells’ invasion through the base-
ment membranes must be preceded by their detachment
from both neighboring cells and the surrounding matrix.
Thus, a critical event in tumor cell invasion is degradation
of a complex network of extracellular macromolecules such
as collagen, proteoglycans, fibronectin, and laminin that act
as a barrier to the spread of cancer cells to distal sites [6, 7].
The majority of matrix degradation is carried out by the
matrix metalloproteinases (MMPs), a family of zinc-
dependent neutral endopeptidases that are collectively capa-
ble of degrading the different components of ECM. The
human MMP gene family consists of several subgroups of
structurally related members, such as collagenases (MMP-1,
MMP-8, MMP-13, MMP-18), gelatinases (MMP-2, MMP-
9), stromelysins (MMP-3, MMP-10, MMP-11), matrilysins
(MMP-7, MMP-26), enamelysins (MMP-18, MMP-19),
metalloelastases (MMP-12), membrane-type metalloprotei-
nases (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24,
MMP-25), and others. These enzymes have been implicated
in the process of tumor growth, invasion, and metastasis [6,
8]. Numerous studies in a variety of tumor types, including
colon carcinoma, demonstrated overexpression of MMPs in
malignant tissues in comparison to adjacent normal tissues.
The increased MMP expression and activity have been
observed to correlate with advanced tumor stage, increased
invasion and metastasis, and shortened survival [9–11].
Furthermore, an accumulating evidence suggests that MMPs
may play an important role in the tissue degradation ob-
served in inflammatory bowel disease [12, 13].
MMP activity is counterbalanced by endogenous inhibitors,
such as specific tissue inhibitors of matrix metalloproteinases
(TIMPs). A family of TIMPs consists of structurally related
proteins (TIMP-1, TIMP-2, TIMP-3, and TIMP-4), revealing
different tissue and cell type specific expression and regulation
patterns [14, 15]. They exert a dual control on the MMPs by
inhibiting both the active form of the MMPs and their activa-
tion process. TIMPs inhibit MMPs by 1:1 stoichiometric bind-
ing and an imbalance between the activation and inhibition of
MMP activity in favor of the MMP activity is believed to play
an important role in the pathophysiology of cancer by facili-
tating the invasion of tumor cells through the ECM [14].
Overexpression of TIMP-1 has been observed to inhibit
some tumor growth and suppress metastatic ability of cancer
cells. Elevated TIMP levels are reported in association with
cancer progression and identified as poor prognostic indica-
tors in several human tumor types such as colorectal cancer,
breast cancer, prostate, and lung cancer [16, 17].
Cancer prevention strongly acknowledges the importance
of diet as dietary factors are the most important environ-
mental risk factors for cancer [18]. Within recent several
years, a large number of naturally occurring health-
enhancing substances of plant origin have been recognized
to have beneficial effects on cancers including colon cancer
and other disorders of the gastrointestinal tract. These
biologically active plant chemicals are now known as
phytochemicals or nutraceuticals [19, 20].
A hexaphosphorylated inositol (IP6) carbohydrate is a
major fiber-associated component of wheat bran, cereals,
legumes, grains, seeds, and nuts and is also widely distrib-
uted in animal cells and tissues at concentrations of about 5–
100 μM [21, 22]. Epidemiological studies have shown that
IP6-rich dietary factors have been associated with reduced
cancer risk and incidence of mortality due to colorectal
cancer [23, 24]. It was noticed that only fiber with high
IP6 content showed negative correlation with colon cancer,
indicating that it could be IP6 and not fiber that suppressed
colon cancer [22]. Moreover, pure IP6 has reproducibly
been demonstrated to have both preventive and therapeutic
effects against various cancers in experimental models in-
cluding that of colon [25, 26]. Anticancer actions of IP6
have been postulated to involve boosting immunity, antiox-
idant properties, anti-apoptotic effects, and signal transduc-
tion reducing cell proliferation and inducing differentiation
of malignant cells [27, 28]. IP6 has been demonstrated to
prevent and abrogate both primary tumor and metastasis in
vivo [29]. It also inhibited metastasis in vitro by affecting
MDA-MB 231 human breast cancer cell adhesion to fibro-
nectin and collagen. The loss of cell adhesion induced by
IP6 and attributed to growth arrest and cell death conferred a
less malignant phenotype. IP6 significantly inhibited the
secretion of MMP-9 from MDA-MB 231 cells as well as
significantly reduced the invasion properties of cancer cells
in vitro [30]. In colorectal cancer cell line Caco-2 IP6
modulated MMP-2, TIMP-1, and TIMP-2 genes expression.
In long lasting culture along with increasing IP6 concen-
trations, the cells expressed lower and lower MMP-2 mRNA
level. In response to IP6, an increased transcriptional
activity of the TIMP-2 gene was accompanied by a decrease
in TIMP-1 gene transcription [31].
The aim of the present study was to examine the influ-
ence of IP6 on the transcriptional activity of selected MMPs
of their three subgroups, i.e., MMP-1, MMP-2, MMP-3,
MMP-9, MMP-10, MMP-13, and that of their TIMP-1 and
TIMP-2 in human colon cancer Caco-2 cells as well as IP6
ability to affect IL-1β-influenced changes in mRNA levels
of the studied genes.
Material and methods
Cell culture
The Caco-2 human colon adenocarcinoma cells (DSMZ,
Braunschweig, Germany) were routinely cultured in RPMI
1640 medium (Sigma Aldrich) supplemented with 10% fetal
bovine serum (GibcoBRL), 100U/ml penicillin and 100 μg/ml
1420 Int J Colorectal Dis (2012) 27:1419–1428
streptomycin (both from Sigma Aldrich), and 10 mM HEPES
(GibcoBRL). They were maintained at 37°C in a 5% CO2
atmosphere. For experiments, the cells were seeded at the
density of 1×106 per 5 ml medium in 21.5 cm2 culture flasks.
After 3 days, the media containing serum were changed to
serum-free media and the cells were cultured for 24 h. They
were then stimulated with 1 ng/ml IL-1β (Sigma Aldrich) for
30 min. Afterwards, the cells were treated with 2.5 mM IP6
as dipotassium salt (Sigma Aldrich; P5681; distilled water
dissolved and pH 7.4 adjusted) for 6, 12, and 24 h. In separate
cultures, cells were incubated with IL-1β or IP6 at the
indicated concentrations and for the indicated times. The
untreated Caco-2 cells were used as the control.
RNA extraction
Total RNA was extracted from control and treated with
IL-1β and IP6 cells with the use of TRIZOL® reagent
(Invitrogen) following the protocol of the manufacturer.
Integrity of the RNA extracts was qualitatively checked
by electrophoresis in 1.0% agarose gel stained with
ethidium bromide. RNA concentration was determined
spectrophotometrically on the basis of absorbance values
at a wavelength of 260 nm using a GeneQuant pro
(Amersham Biosciences).
Real-time QRT-PCR assay
Detection of the expression of MMP and TIMP mRNAs
was carried out using a QRT-PCR technique with a
SYBR Green chemistry (SYBR Green Quantitect RT-
PCR Kit, Qiagen) and Opticon™ DNA Engine Contin-
uous Fluorescence detector (MJ Research) as described
previously [31]. Oligonucleotide primers specific for
MMP-1, MMP-2, MMP-3, MMP-9, MMP-10, MMP-
13, TIMP-1, and TIMP-2 mRNAs were designed using
Primer Express 2.0 software (PE Applied Biosystems,
USA; Table 1). QRT-PCR assay was performed in trip-
licate for each sample. The thermal profile for one-step
RT-PCR was as follows: 50°C for 30 min for reverse
transcription and 95°C for 15 min followed by 45
cycles at 94°C for 15 s, 55°C for 30 s, and 72°C for
45 s for amplification. Following RT-PCR, the samples
were subjected to temperature ramp from 60°C to 95°C
at the rate of 0.2°C/s with continuous fluorescence
monitoring for melting curve analysis. The mRNA copy
numbers of examined genes were determined on the
basis of the commercially available standard of β-
actin (TaqMan DNA Template Reagent Kit, Applied
Biosystems). The obtained results of mRNA copy
number were recalculated per μg of total RNA. The
specificity of RT-PCR reaction was confirmed by deter-
mining the characteristic temperature of melting for
each amplimer and by 6% polyacrylamide gel electro-
phoresis of RT-PCR products with their visualization
using silver staining.
Statistical analysis
Statistical analysis was carried out using the Statistica PL
9.0 software. The one-way ANOVA followed by post hoc
Tukey’s test were applied to evaluate differences in the
expression of examined genes between untreated cells and
cells treated with IP6 and IL-1β. All the results are
expressed as means±SD. Values of p<0.05 were considered
as statistically significant.
Table 1 Characteristics of
primers used in experiment
bp base pair, TM temperature of
melting
Gene Primer sequence Product amplified (bp) TM (°C)
MMP1 F: 5′-GCTCATGAACTCGGCCATTCTCTTGGACT-3′ 281 81
R: 5′-CGGGTAGAAGGGATTTGTGCGCATGTA-3′
MMP2 F: 5′-TCCACTGTTGGTGGGAACTCA-3′ 121 83
R: 5′-TGGTCGCACACCACATCTTT-3′
MMP3 F: 5′-CCGAGAAATGCAGAAGTTCCTTGGATTGG-3′ 131 82
R: 5′-TCGGGATGCCAGGAAAGGTTCTGAAGTG-3′
MMP9 F: 5′-TTCTGCCCCAGCGAGAGA-3′ 101 81
R: 5′-GTGCAGGCGGAGTAGGATTG-3′
MMP10 F: 5′ TCTTGCATTCCTTGTGCTGTTG 3′ 101 81
R: 5′ ATTGCTGGGCAAGATCCTTGT 3′
MMP13 F: 5′-ACACCTACACCGGCAAAAGC-3′ 121 79
R: 5′-CATTTGTCTGGCGTTTTTGGA-3′
TIMP1 F: 5′-GCCATGGAGAGTGTCTGCGGATACTTCC-3′ 118 86
R: 5′-GCCACGAAACTGCAGGTAGTGATGT-3′
TIMP2 F: 5′-CCCCAAGCAGGAGTTTCTCGACATCG-3′ 100 82
R: 5′-TGGACCAGTCGAAACCCTTGGAGGCT-3′
Int J Colorectal Dis (2012) 27:1419–1428 1421
Results
The basal mRNA expression of matrix metalloproteinases
of collagenase, gelatinase, and stromelysin subgroups
and of their tissue inhibitors in Caco-2 human colon
adenocarcinoma cells
The effect of IL-1β and IP6 on the expression of
mRNA of MMP-1, MMP-2, MMP-3, MMP-9, MMP-
10, and MMP-13 and that of their tissue inhibitors
TIMP-1 and TIMP-2 in colon cancer cells using real-
time QRT-PCR assay was determined. The transcription-
al activity of all examined MMP genes except that of
MMP-9 was detected in unstimulated Caco-2 cells. The
cells also exhibited the expression of both TIMPs under
standard conditions. The highest level of transcription
was manifested by MMP-1 and TIMP-2 genes (Fig. 1).
The influence of IL-1β on MMP and TIMP genes
expression
Stimulation of Caco-2 with 1 ng/ml of IL-1β for 6–
24 h resulted in an upregulation of MMP-1, MMP-9,
MMP-10, TIMP-1, and TIMP-2 genes as compared with
untreated cells (p<0.05) (Figs. 2a, 3b, 4b, and 5). A
significantly higher MMP-13 and MMP-3 mRNA levels
were determined following IL-1β cell treatment for 6–
12 h than in controls (Figs. 2b and 4a). The MMP-2
expression was markedly induced in response to IL-1β
after 12 h (Fig. 3a).
Changes in constitutive and IL-1β-stimulated expression
of genes encoding collagenases in Caco-2 cells treated
with IP6
In a time course experiment, 2.5 mM IP6 had no
influence on MMP-1 expression (p>0.05; Tukey test;
Fig. 2a). Statistical analysis revealed significant decrease
in the MMP-1 gene expression in cells exposed to IL-
1β and IP6 for 6 h compared to the cultures treated
with IL-1β only (p<0.001; Tukey test). IP6 downregu-
lated constitutive transcriptional activity of MMP-13
gene in Caco-2 and a statistically significant difference
in this gene expression between control and IP6-treated
cells was observed after 24 h (p<0.001; Tukey test). No
marked changes in MMP-13 gene activity were demon-
strated in IL-1β-stimulated cells and those treated with
IL-1β and IP6 for 6–24 h (Fig. 2b).
Fig. 1 The basal expression of MMP and TIMP mRNAs in Caco-2
cells.The cells were seeded at the density of 1×106 and grown as
described in the “Materials and methods” section. The real-time
QRT-PCR was performed for MMP and TIMP genes. The Caco-2
did not show the expression of MMP-9 gene. Graph represents the
mean±SD of three individual experiments
Fig. 2 Expression of genes encoding collagenases in Caco-2 cells as
determined by real-time RT-PCR. Comparison of the copy number of a
MMP-1 and bMMP-13 mRNAs per 1 μg of total RNA in Caco-2 cells
treated with 2.5 mM IP6 and 1 ng/ml IL-1β for 6, 12, and 24 h (the
results are presented as mean±SD of three separate experiments; *p<
0.05 vs control Caco-2 cells; #p<0.05 vs IL-1β-stimulated cells)
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Changes in constitutive and IL-1β-stimulated expression
of genes encoding gelatinases in Caco-2 cells treated
with IP6
A comparison of expression of genes encoding gelatinases
in the control cells and cultures treated with IP6 and IL-1β
for 6–12–24 h showed significant differences (Fig. 3). Cells
incubated with 2.5 mM IP6 for 6 (p00.049), 12 (p00.715),
and 24 h (p00.002) presented decreased MMP-2 transcript
level in comparison to control cells. At time points of 6 and
24 h, transcriptional activity of this gene in cultures treated
with IL-1β only and those incubated with both IL-1β and
IP6 revealed similar levels (p>0.05). After 12 h, statistically
significant decrease in mRNA values for MMP-2 was
observed in cells exposed to IL-1β and IP6 in relation to
cells treated with IL-1β only (p00.0212; Fig. 3a).
Caco-2 cells did not reveal the expression of MMP-9
gene under both basal conditions and following treatment
with IP6 at the analyzed time intervals. However, IL-1β
strongly induced MMP-9 gene expression in the cells and
in short-lasting cultures (6 h), IL-1β-induced transcription
of this gene was remarkably downregulated by IP6 (p0
0.0019). There were no differences in MMP-9 transcript
level between IL-1β-stimulated cells and cells exposed to
IL-1β and IP6 for both 12 and 24 h (Fig. 3b).
Changes in constitutive and IL-1β-stimulated expression
of genes encoding stromelysins in Caco-2 cells treated
with IP6
Treatment of Caco-2 cells with 2.5 mM IP6 for 24 h resulted
in statistically significant decrease in MMP-3 gene
Fig. 3 Expression of genes encoding gelatinases in Caco-2 cells as
determined by real-time RT-PCR. Comparison of the copy number of a
MMP-2 and b MMP-9 mRNAs per 1 μg of total RNA in Caco-2 cells
treated with 2.5 mM IP6 and 1 ng/ml IL-1β for 6, 12, and 24 h. In
Caco-2, cells did not detect the expression of MMP-9 gene either under
normal conditions or following treatment with 2.5 mM IP6 for each
interaction time (the results are presented as mean±SD of three
separate experiments; *p<0.05 vs control Caco-2 cells; #p<0.05
vs IL-1β-stimulated cells)
Fig. 4 Expression of genes encoding stromelysins in Caco-2 cells as
determined by real-time RT-PCR. Comparison of the copy number of a
MMP-3 and bMMP-10 mRNAs per 1 μg of total RNA in Caco-2 cells
treated with 2.5 mM IP6 and 1 ng/ml IL-1β for 6, 12, and 24 h (the
results are presented as mean±SD of three separate experiments; *p<
0.05 vs control Caco-2 cells; #p<0.05 vs IL-1β-stimulated cells)
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expression in comparison to control cells (p00.0096). The
levels of MMP-3 mRNA in IL-1β-stimulated cells and cells
treated with IL-1β and IP6 revealed no statistically signifi-
cant differences after 6–12–24 h (Fig. 4a), indicating no
influence of IP6 on enhanced expression of MMP-3 pro-
moted by IL-1β. Furthermore, MMP-10 gene transcription
appeared to be highly responsive to stimulatory action of IL-
1β and IP6 had no effect on the basal transcriptional activity
of this gene (p>0.05). Statistically insignificant differences
in mRNA levels of MMP-10 in cells exposed to IL-1β alone
and treated with IL-1β/IP6 for 6–24 h were noted (Fig. 4b).
Changes in constitutive and IL-1β-stimulated
expression of genes encoding tissue inhibitors of matrix
metalloproteinases in Caco-2 cells treated with IP6
The level of TIMP-1 mRNA expression was significantly
lower in Caco-2 cells incubated with IP6 for 24 h than in
untreated cells (p00.0158). However, 12 h incubation of
cells with IP6 resulted in higher level of TIMP-2
mRNA compared to control (p00.0007). The TIMP-2
gene expression increased by IL-1β at 6 h was significantly
downregulated by IP6 (p00.0039; Fig. 5).
Discussion
The family of matrix metalloproteinases and their tissue
inhibitors play an essential role in a variety of pathologic
and physiologic conditions. MMPs can degrade essentially
all extracellular matrix components and thus, contribute to
every stage of tumor progression including tumor cell inva-
sion and metastasis. [8, 32]. The activity of MMPs is regu-
lated at several levels, but many researches underline that
transcriptional regulation of the genes expression beside the
activation of latent proenzyme forms and interaction with
TIMPs could be considered most important mechanism [12,
32, 33]. Thus, it is thought that the local balance of MMP
expression and activation versus the level of TIMP deter-
mines the extent of tissue destruction mediated by MMPs.
Studies have shown that MMP protein concentrations cor-
relate well with mRNA expression in vitro [12]. Therefore,
in the present study, we concentrated our attention on MMP
and TIMP genes expression at transcriptional level. Quanti-
tative mRNA expression of MMP-1, MMP-2, MMP-3,
MMP-9, MMP-10, MMP-13, and TIMP-1 and TIMP-2
was evaluated simultaneously by real-time RT-PCR in
human colon cancer cells Caco-2.
MMP transcripts are frequently expressed at low or un-
detectable levels but their level substantially increases in
tissues undergoing remodeling, such as in inflammation
and cancer [33]. The main source of MMPs in most tumors
is stromal fibroblasts. Moreover, inflammatory cells infil-
trating tumor as well as inflamed colonic mucosa also pro-
duce MMPs. Recruitment of these cells appears to be largely
enhanced by MMPs produced within the tumor environment
[34]. Moreover, inflammatory cells secrete cytokines which
enhance MMPs expression by tumor and stromal cells [35].
IL-1β, besides IL-6 and TNF-α, is the most abundantly
expressed cytokine, both in normal and inflamed mucosa
[36]. Activation of protein kinase C (PKC), mitogen-
activated protein kinases (MAPKs), activator protein-1
(AP-1), and nuclear factor κB (NF-κB) is suggested to be
an essential event in the cascade leading to the stimulation
of MMPs and TIMPs gene expression in response to
proinflammatory cytokines (IL-1β, TNF-α) [35, 37, 38].
The results of the present study revealed a distinct pattern
of basal and IL-1β-stimulated expression of MMPs and
TIMPs mRNA in human colon carcinoma cells. Under
normal conditions, Caco-2 cells constitutively expressed
genes encoding MMP-1, MMP-2, MMP-3, MMP-10,
Fig. 5 Expression of genes encoding tissue inhibitors of matrix metal-
loproteinases in Caco-2 cells as determined by real-time RT-PCR.
Comparison of the copy number of a TIMP-1 and b TIMP-2 mRNAs
per 1 μg of total RNA in Caco-2 cells treated with 2.5 mM IP6 and
1 ng/ml IL-1β for 6, 12, and 24 h (the results are presented as mean±
SD of three separate experiments; *p<0.05 vs control Caco-2 cells;
#p<0.05 vs IL-1β-stimulated cells)
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MMP-13, and their tissue inhibitors TIMP-1 and TIMP-2,
whereas MMP-9 transcription was not detected. This obser-
vation can be referred to the work of Gan et al. [39], which
demonstrated detectable but very low levels of MMP-9
mRNA in Caco-2 cells in the absence of inflammatory
stimuli. Among examined MMPs and their inhibitors, we
detected the highest amounts of collagenase-1 (MMP-1) and
TIMP-2 mRNAs. MMP-1 is expressed by a variety of tumor
cells, where its levels are constitutively high even in the
absence of apparent external stimuli [40, 41]. The col-
lagenases are the foremost enzymes capable of cleaving
triple helix of collagens type I, II, III, and V into frag-
ments subsequently degraded by other MMPs, such as
gelatinases [35, 41]. Bendardaf et al. [41] suggested that
the intense expression of interstitial collagenases, such
as MMP-1, is required, mostly in the initial stages of
tumor invasion and metastasis because tumor invasion is
facilitated by degradation of interstitial stroma, the main
component of ECM.
The addition of IL-β (1 ng/ml) to the cell cultures
resulted in enhancement of all MMPs as well as TIMPs
transcript levels in a time-dependent manner. IL-1β was
capable of activating the transcription of TIMPs and each
of MMPs except MMP-2 after 6 h, and overexpression of
MMP-2 gene was noted after 12 h stimulation. The differ-
ences in the activation time of MMP genes may be
explained by the fact that those of them inducible by extra-
cellular stimuli (MMP-1, MMP-3, MMP-7, MMP-9, MMP-
10, MMP-12, and MMP-13) possess an AP-1 transcription
factor binding site in the promoter. On the contrary, MMP-2,
MMP-11, and MMP-14 genes do not contain AP-1 elements
[35]. The human MMP-2 gene promoter contains AP-2
transcription factor binding site [35, 42].
Our observation on MMP expression remains in agree-
ment with other findings. Kermorgant et al. [43] confirmed
the presence of MMP-2 and MMP-1 but not MMP-9 mRNA
in Caco-2 cells by RT-PCR. In the absence of inflammatory
stimuli, Caco-2 cells expressed low levels of MMP-9
mRNA. Stimulation of cells with IL-1β induced the pro-
duction of MMP-9 [39]. Claramunt et al. [44] found that in
untreated Caco-2 cells, MMP-2 was the predominant gelat-
inase, whereas MMP-9 was negligible one. However, cyto-
kine treatment resulted in a significant dose-dependent
upregulation of MMP-9 activity in those cells. On the con-
trary, MMP-2 remained unchanged by the cytokine treat-
ment. The authors concluded that MMP-9 is inducible and
its gene promoter region is highly responsive to most
growth factors and cytokines, whereas MMP-2 is expressed
constitutively by most cells and appears to be moderately
induced or repressed. Salmela et al. [45] demonstrated that
IL-1β at 24 h upregulated MMP-7 and MMP-10 expression
in HT-29, WiDr, and Caco-2 gut epithelial cell lines. In
Caco-2 cells, IL-1β increased collagenase-1 expression at
least threefold compared to unstimulated control samples.
Roeb et al. [9] postulated that inhibiting overexpression of
MMPs may be a useful preventive or therapeutic adjunct in
colorectal cancer. According to the opinion of Brinckerhoff
et al. [40], signal transduction pathways participating in
MMP gene expression have lead to new therapeutic strate-
gies of cancer prevention and treatment. In the last years,
many drugs aiming at MMP downregulation have been
synthesized and are undergoing clinical trials in various
human cancers [46, 47]. Inhibitors of MMPs (MMPIs) fall
into three pharmacologic species: collagen peptidomimetics,
tetracycline derivatives, and bisphosphonates [14]. Peptido-
mimetic MMP inhibitors are pseudopeptide derivatives that
mimic the structure of collagen at the site where MMP binds
to cleave it. The inhibitor binds reversibly at the active site
of the MMP in a stereospecific manner and chelates the zinc
with, in most cases, a hydroxamic acid functional group, on
the enzyme activation site. The earliest generation of these
inhibitors (batimastat) had low water solubility and was not
orally available. The next generation of inhibitors (marima-
stat, prinomastat) was orally available, but they were fre-
quently linked with musculoskeletal toxicity, probably due
to their off-target effects on non-MMP metalloproteinases.
These agents are relatively nonspecific, inhibiting the activ-
ity of MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9 [14,
47]. Another group of MMPIs are tetracyclines (tetracy-
cline, doxycycline, and minocycline) and its chemically
modified derivatives (metastat), which do not possess anti-
biotic activities. These compounds effectively inhibit a
broad range of MMPs through their ability to chelate Zn2+
ion on the active site of enzymes, thus changing their
interactions with substrates; it can also downregulate the
transcription of MMPs mRNA. [48, 49]. These agents in-
hibit both gelatinases and collagenases. The bisphospho-
nates are a synthetic compounds with a high affinity for
the hydroxyapatite crystal of bone. These drugs are used in
instability of calcium homeostasis and for the palliation and
prevention of bone metastases in patients with breast cancer
and multiple myeloma. The agent exerts the effect on MMPs
via inhibition of their enzymatic activity [14]. Pharmacolog-
ical inhibition of MMPs relies on the ability of drugs to
chelate the metal ions. Their property makes them nonse-
lective inhibitors targeting multiple MMPs, since the Zn2+ is
present in the catalytic domain of all MMPs, so broad range
blockade of multiple MMPs would not be expected to be
useful [50]. The lack of therapeutic success of MMP inhib-
itors in cancer treatment has largely been due to toxicity of
the drugs on normal tissues as well as conflicting roles in
both promoting and reducing tumor metastastasis [51].
Moreover, the drugs were not effective because they were
employed too late, in advanced, metastatic stage of cancer
[47, 52]. Currently, there are used highly specific monoclo-
nal antibodies against MMPs; however, the difficulty of
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producing macromolecular proteins and the parenteral ad-
ministration of drugs limit their therapeutic potential [53].
The great potential for chemoprevention and therapeutic
achievement could have agents capable of suppressing nu-
merous intracellular signaling pathways [54]. Inositol hex-
aphosphate, a natural dietary component, exerts anti-cancer
influence on tumor cells via phosphatidylinositol-3 kinase
(PI3K), MAPK, PKC, AP-1, and NFκB (Fig. 6). It has been
shown to block PKC and PI3K and inhibit AP-1 as well as
MAPK activation [22, 26, 55]. Our previously published
data demonstrated that IP6 modulated the expression of p65
subunit of nuclear factor κB and its IκBα inhibitor in the
intestinal epithelial cells [56]. Thus, IP6 may exhibit its own
action on key elements of MMP genes expression pathways
both in untreated and stimulated by interleukin-1β.
The main aim of the current study was to evaluate the
effect of phytic acid on the expression of genes encoding
metalloproteinases and their tissue inhibitors in IL-1β-
treated colon cancer Caco-2 cells. Studies concerning the
influence of IP6 on the expression of MMPs and TIMPs in
IL-1β-stimulated cells have not yet been published. A re-
cent experiment by Claramunt and co-workers [44] has
demonstrated that curcumin, naturally occurring nutriceuti-
cal, was able to significantly downregulate MMP-9 activity
in Caco-2 cells stimulated by pro-inflammatory cytokines.
As observed in the present study, treatment of Caco-2 cells
with 2.5 mM IP6 for 24 h showed markedly decreased
MMP-13 and MMP-3 genes expression in comparison to
control. IP6 also influenced a decrease in MMP2 transcript
level after 6 and 24 h incubation. The level of TIMP-1 gene
expression in cells exposed to IP6 for 24 h was lower than in
untreated cells, and at 12 h incubation with IP6, the cells
exhibited higher level of TIMP-2 mRNA. IP6 counteracted
the stimulatory effect of IL-1β on MMP-1, MMP-9, and
TIMP-2 genes expression in Caco-2 cells by decreasing
their mRNA levels in 6 h lasting cultures. After 12 h, IL-
1β-induced MMP-2 mRNA expression was remarkably
downregulated by IP6.
In conclusion, the current data suggest that proinflamma-
tory cytokines of which IL-1β is the major representative
may upregulate MMP and TIMP expression in gut epithelial
cells which indicates that inflammatory reactions leading to
cytokine release may stimulate MMPs and their inhibitors
expression these cells. MMPs could then contribute to in-
testinal tissue destruction and propagation of inflammation
and invasive capacity of tumor cells. Moreover, inositol
hexaphosphate at the concentration of 2.5 mM was able to
inhibit IL-1β-induced MMP-1, MMP-2, MMP-9, and
TIMP-2 genes expression at transcriptional level in Caco-2
cells. In addition, the decrease in MMP-2, MMP-3, MMP-
13, and TIMP-1 basal transcripts level could be evoked by
2.5 mM IP6 after relatively longer time of its action. Thus, it
can be suggested that IP6 may exert its anti-metastatic
activity through modulation of MMP and TIMP genes
expression to prevent cancer cell migration and invasion.
Further investigation on IP6 is clearly warranted, the
more that as a naturally occurring product, in contrast with
conventional anti-cancer agents, IP6 offers safety and dem-
onstrates specific activity on tumor cells without affecting
the normal cells. Thus, inositol hexaphosphate could be
used not only in promotion but also in all stages of cancer
progression by downregulation of matrix metalloproteinases
expression.
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